Gene therapy-focused Genetix Pharmaceuticals raises $35 million
This article was originally published in Scrip
Executive Summary
Genetix Pharmaceuticals, which is developing gene therapies for genetic disorders, has raised $35 million in series B funds. The round included new investors Third Rock Ventures and Genzyme Ventures, with existing investors TVM Capital, Forbion and Easton Capital also participating.